SCHEMBL15064428

SCHEMBL15064428

COc1ccc(-c2nn(C(C)C)c3cccnc23)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 2/20 0.40
PDE1A P54750 5/20 0.40
PDE1B Q01064 5/20 0.40
PDE1C Q14123 5/20 0.40
PIK3CD O00329 2/20 0.38
HSD17B1 P14061 1/20 0.36
HSD17B2 P37059 1/20 0.36
JAK2 O60674 1/20 0.36
CYP19A1 P11511 1/20 0.36
MAOB P27338 1/20 0.36
CYP2A6 P11509 2/20 0.36
PRKDC P78527 2/20 0.36
ABL1 P00519 1/20 0.36
EGFR P00533 1/20 0.36
HCK P08631 1/20 0.36
SRC P12931 1/20 0.36
KDR P35968 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15064660 0.82 KDR (0.37) MTORPDE1APDE1BPDE1CPIK3CD
SCHEMBL15064773 0.81 HDAC1 (0.37) MTORPDE1APDE1BPDE1CPIK3CD
SCHEMBL15064667 0.80 FYN (0.37) PDE1APDE1BPDE1CHSD17B1HSD17B2
SCHEMBL18561572 0.78 KDR (0.47) MTORPDE1APDE1BPDE1CPIK3CD
SCHEMBL15064701 0.72 PDE1A (0.39) MTORPDE1APDE1BPDE1CPIK3CD
SCHEMBL10094474 0.72 HSD17B1 (0.42) MTORPIK3CDHSD17B1HSD17B2CYP19A1
SCHEMBL13509089 0.69 KDR (0.45) MTORPIK3CDHSD17B1HSD17B2JAK2
SCHEMBL10094701 0.69 CYP2A6 (0.57) MTORPIK3CDHSD17B1HSD17B2CYP19A1
SCHEMBL569294 0.69 PDE1A (0.39) MTORPDE1APDE1BPDE1CPIK3CD
SCHEMBL18868085 0.68 SRC (0.72) MTORPIK3CDPRKDCABL1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601192-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICALS CO (JP) 2017-03-01 EP disclosed
US-9029536-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-12 US disclosed
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS PDE10A, PDE3A, PDE2A MTOR 3598/4885PDE1A 15/4885PDE1B 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.